- Home
- UPST vs TARS Comparison
UPST vs TARS Comparison
Compare UPST & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | TARS |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UPST | TARS |
|---|---|---|
| Price | $27.63 | $60.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | $45.84 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 3.5M | 1.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,043,857,000.00 | $451,360,000.00 |
| Revenue This Year | $34.45 | $56.43 |
| Revenue Next Year | $32.64 | $30.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 63.99 | ★ 146.71 |
| 52 Week Low | $23.97 | $38.51 |
| 52 Week High | $85.31 | $85.25 |
Technical Indicators
Market Signals| Indicator | UPST | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 49.15 |
| Support Level | $25.18 | $56.05 |
| Resistance Level | $34.84 | $67.14 |
| Average True Range (ATR) | 1.50 | 3.38 |
| MACD | -0.59 | -0.11 |
| Stochastic Oscillator | 11.13 | 37.27 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.